A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/17 (2006.01) A61P 31/00 (2006.01) A61P 37/04 (2006.01) C07K 14/47 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2372128
The present invention relates to the use of a composition comprising at least one mannan-binding lectin (MBL) subunit, or at least one mannan-binding lectin (MBL) oligomer comprising the at least one mannan-binding lectin (MBL) subunit, in the manufacture of a medicament for prophylaxis and/or treatment of infection. In particular the invention relates to prophylaxis and/or treatment of infection in an individual having an immunocompromised condition; and/or an individual being at risk of acquiring an immunocompromised condition resulting from a medical treatment. The present invention is particularly relevant for prophylaxis and/or treatment of infection in individuals suffering from neutropenia, in particular as prophylaxis and/or treatment of infection in individuals receiving or going to receive chemotherapy or similar treatment. The individuals may be treated independent on their serum MBL level, and it has been shown that in particular individuals having a serum MBL level in the range of from 50 ng/ml serum to 500 ng/ml serum may benefit from the prophylaxis and/or treatment.
La présente invention concerne l'utilisation d'une composition comprenant au moins une sous-unité de lectine de liaison au mannane (MBL) ou au moins un oligomère de lectine de liaison au mannane (MBL) comprenant la sous-unité de lectine de liaison au mannane (MBL), dans la fabrication d'un médicament destiné à la prophylaxie et/ou au traitement d'une infection. L'invention concerne en particulier la prophylaxie et/ou le traitement d'une infection chez un individu immunodéprimé ; et/ou chez un individu présentant un risque d'immunodépression suite à un traitement médical. La présente invention est particulièrement indiquée pour la prophylaxie et/ou le traitement d'une infection chez des individus souffrant de neutropénie, notamment pour la prophylaxie et/ou le traitement d'une infection chez des individus subissant ou devant subir une chimiothérapie ou un traitement similaire. Les individus peuvent être traités indépendamment de leur taux de MBL dans le sérum et on a découvert que la prophylaxie et/ou le traitement était particulièrement avantageux pour les individus présentant un taux de MBL dans le sérum compris entre 50 et 500 ng/ml.
Jensenius Jens Christian
Thiel Steffen
Deeth Williams Wall Llp
Jensenius Jens Christian
Thiel Steffen
LandOfFree
Novel indications of mannan-binding lectin (mbl) in the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel indications of mannan-binding lectin (mbl) in the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel indications of mannan-binding lectin (mbl) in the... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1462812